Spyre Therapeutics, Inc. SYRE Interest proceeds from maturities of zero coupon U.S. Treasury Bills
Interest proceeds from maturities of zero coupon U.S. Treasury Bills at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:InterestProceedsDebtSecurities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s interest proceeds from maturities of zero coupon u.s. treasury bills.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s interest proceeds from maturities of zero coupon U.S. treasury bills?
- Spyre Therapeutics, Inc. (SYRE) reported interest proceeds from maturities of zero coupon U.S. treasury bills of $372K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s interest proceeds from maturities of zero coupon U.S. treasury bills changed year-over-year?
- Spyre Therapeutics, Inc.'s interest proceeds from maturities of zero coupon U.S. treasury bills decreased by 29.8% year-over-year, from $530K to $372K.
- What does interest proceeds from maturities of zero coupon U.S. treasury bills mean?
- This metric tracks the cash received from interest payments or the maturity of debt securities held by the company. It represents the yield generated from the company's cash and cash equivalents or short-term investment portfolio. It is a key indicator of treasury performance and liquidity management.